Structure Therapeutics American Stock Market Value
| GPCR Stock | 68.36 3.05 4.27% |
| Symbol | Structure |
Can Biotechnology industry sustain growth momentum? Does Structure have expansion opportunities? Factors like these will boost the valuation of Structure Therapeutics. Market participants price Structure higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Structure Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Structure Therapeutics requires distinguishing between market price and book value, where the latter reflects Structure's accounting equity. The concept of intrinsic value - what Structure Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Structure Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Structure Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Structure Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Structure Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Structure Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Structure Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Structure Therapeutics.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Structure Therapeutics on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Structure Therapeutics American or generate 0.0% return on investment in Structure Therapeutics over 90 days. Structure Therapeutics is related to or competes with Edgewise Therapeutics, Viridian Therapeutics, Uniqure NV, Ocular Therapeutix, Nuvation Bio, Galapagos, and Mesoblast. Structure Therapeutics is entity of United States More
Structure Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Structure Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Structure Therapeutics American upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.12 | |||
| Information Ratio | 0.1128 | |||
| Maximum Drawdown | 112.39 | |||
| Value At Risk | (7.09) | |||
| Potential Upside | 8.23 |
Structure Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Structure Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Structure Therapeutics' standard deviation. In reality, there are many statistical measures that can use Structure Therapeutics historical prices to predict the future Structure Therapeutics' volatility.| Risk Adjusted Performance | 0.1014 | |||
| Jensen Alpha | 1.57 | |||
| Total Risk Alpha | 0.9234 | |||
| Sortino Ratio | 0.3657 | |||
| Treynor Ratio | (2.03) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Structure Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Structure Therapeutics February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1014 | |||
| Market Risk Adjusted Performance | (2.02) | |||
| Mean Deviation | 5.16 | |||
| Semi Deviation | 3.49 | |||
| Downside Deviation | 4.12 | |||
| Coefficient Of Variation | 860.2 | |||
| Standard Deviation | 13.35 | |||
| Variance | 178.18 | |||
| Information Ratio | 0.1128 | |||
| Jensen Alpha | 1.57 | |||
| Total Risk Alpha | 0.9234 | |||
| Sortino Ratio | 0.3657 | |||
| Treynor Ratio | (2.03) | |||
| Maximum Drawdown | 112.39 | |||
| Value At Risk | (7.09) | |||
| Potential Upside | 8.23 | |||
| Downside Variance | 16.94 | |||
| Semi Variance | 12.2 | |||
| Expected Short fall | (6.89) | |||
| Skewness | 6.83 | |||
| Kurtosis | 52.07 |
Structure Therapeutics Backtested Returns
Structure Therapeutics is not too volatile given 3 months investment horizon. Structure Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.13, which indicates the firm had a 0.13 % return per unit of risk over the last 3 months. We were able to break down twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.8% are justified by taking the suggested risk. Use Structure Therapeutics Coefficient Of Variation of 860.2, semi deviation of 3.49, and Risk Adjusted Performance of 0.1014 to evaluate company specific risk that cannot be diversified away. Structure Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The entity has a beta of -0.76, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Structure Therapeutics are expected to decrease at a much lower rate. During the bear market, Structure Therapeutics is likely to outperform the market. Use Structure Therapeutics value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on Structure Therapeutics.
Auto-correlation | 0.47 |
Average predictability
Structure Therapeutics American has average predictability. Overlapping area represents the amount of predictability between Structure Therapeutics time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Structure Therapeutics price movement. The serial correlation of 0.47 indicates that about 47.0% of current Structure Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.47 | |
| Spearman Rank Test | 0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 90.15 |
Pair Trading with Structure Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Structure Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Structure Stock
| 0.77 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
| 0.72 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.61 | EQ | Equillium | PairCorr |
Moving against Structure Stock
| 0.65 | OSE | OSE Pharma SA | PairCorr |
| 0.58 | RAC | Race Oncology Earnings Call This Week | PairCorr |
| 0.54 | DRMA | Dermata Therapeutics | PairCorr |
| 0.5 | VCEL | Vericel Corp Ord Earnings Call This Week | PairCorr |
| 0.46 | VCYT | Veracyte Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Structure Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Structure Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Structure Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Structure Therapeutics American to buy it.
The correlation of Structure Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Structure Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Structure Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Structure Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.